OCAM
NVCR icon

Onex Canada Asset Management’s NovoCure NVCR Stock Holding History

Onex Canada Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-104,359
Closed -$5.47M – 111
2018
Q3 		$5.47M Buy
+104,359
New +$4.15M 0.24% 49

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Onex Canada Asset Management's NVCR Position: Q4 2018 in Review

Onex Canada Asset Management sold out of NovoCure (NVCR) in Q4 2018, closing a stake of 104,359 shares — an estimated $5.47M sold.

Onex Canada Asset Management first reported a position in NVCR in Q3 2018 and held it in 1 quarter. The position peaked at $5.47M in Q3 2018. 166 funds tracked by Wall St. Rank hold NVCR as of Q4 2018.

  • Onex Canada Asset Management reported no remaining NovoCure position as of Q4 2018 after selling out during the quarter.
  • Onex Canada Asset Management sold 104,359 NovoCure shares in Q4 2018, an estimated $5.47M.
  • Onex Canada Asset Management first reported a position in NovoCure in Q3 2018 and held it in 1 quarter.
  • Onex Canada Asset Management's NovoCure position peaked at $5.47M in Q3 2018.
  • 166 funds tracked by Wall St. Rank held NovoCure as of Q4 2018.

Based on Onex Canada Asset Management's 13F filing for Q4 2018, filed 12 Feb 2019.